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Article hightlights 35 
Type of research: Retrospective registry study using competing risk analysis 36 
Key findings: In overall series of 580 infrapopliteal open or endovascular revascularizations, 37 
diabetes, rheumatoid arthritis, increased number of affected angiosomes and the absence of a 38 
complete pedal arch were independent predictors of major amputation. When patients who 39 
underwent bypass surgery and endovascular treatment were analysed separately, it turned out 40 
that diabetes was the only risk factor for major amputation after bypass whereas after 41 
endovascular revascularization, complete pedal arch and angiosome-targeted revascularization  42 
were associated with a lower risk of major amputation. 43 
Take home message: Angiosome-targeted revascularization is important in patients who 44 
undergo endovascular revascularization due to EVT especially if pedal arch is incomplete. 45 
 46 
Abstract 47 
Introduction: In the context of chronic limb threatening ischemia (CLTI), the prognostic impact 48 
of angiosome-targeted revascularization and of the status of the pedal arch are debated.  49 
Materials and method: This series includes 580 patients who underwent endovascular 50 
(n=407) and surgical revascularization (n=173) of the infrapopliteal arteries for CLTI associated 51 
with foot ulcer or gangrene. The risk of major amputation after infrapopliteal revascularization 52 
was assessed by a competing risk approach. A subanalysis was made separately for patients who 53 
underwent endovascular or open surgical revascualrization. 54 
Results: At 2 years, survival was 65.1% and leg salvage was 76.1%. Multivariable competing 55 
risk analysis showed that C-reactive protein≥ 10 mg/dL, diabetes, rheumatoid arthritis, 56 
increased number of affected angiosomes and the incomplete or total absence of pedal arch 57 
compared to complete pedal arch were independent predictors of major amputation after 58 
infrapopliteal revascularization. Multivariable analysis showed increasing risk estimates of 59 
major amputation in patients with incomplete (SHR 2.131, 95%CI 1.282-3.543) and no 60 
visualized pedal arch (SHR 3.022, 95%CI 1.553-5.883) compared to complete pedal arch. 61 
Pedal arch was important even if angiosome-targeted revascularization was achieved:  62 
Angiosome-directed revascularization in presence of complete pedal arch had a lower risk of 63 
major amputation (adjusted SHR 0.463, 95%CI 0.240-0.894) compared to angiosome-directed 64 
revascularization without complete pedal arch.  65 
In the subanalysis, among patients who underwent endovascular revascularization, complete 66 
pedal arch (SHR 0.509, 95%CI 0.286-0.905) and angiosome-targeted revascularization (SHR 67 
0.613, 95%CI 0.394-0.956) were associated with a lower risk of major amputation. 68 
Conclusions: Competing risk analysis showed that a patent pedal arch had significant impact on 69 
leg salvage and that the subset of patients undergoing endovascular procedure may most benefit 70 
of an angiosome-targeted revascularization.  71 
 72 
Introduction 73 
Chronic limb threatening ischemia is associated with a high risk of major amputation (1). 74 
Subsets of patients with significant comorbidities are also at a formidable risk of early death 75 
after lower limb revascularization (2). In this regard, patients’ death is a competing risk in the 76 
evaluation of the efficacy of leg salvage procedures as the occurrence of mortality after 77 
revascularization precludes the ability to observe the outcome of interest (3,4).  78 
The angiosome theory in patients with chronic limb threatening ischemia has been applied in 79 
vascular surgery during the last years. Although the results from several retrospective patient 80 
series support the angiosome concept, (5,6)  the theory has been criticized. The main criticism is 81 
that there are several other important factors that have an impact on leg salvage than angiosome 82 
concept itself. The importance of angiosome concept and status of pedal arch has been studied 83 
earlier in small series where the proper subgroup analyses has not been possible, but they 84 
emphasize the importance of complete pedal arch ( (7–10).   85 
Thus, in the context of infrapopliteal revascularization for foot ulcer or gangrene, the prognostic 86 
impact of angiosome-targeted revascularization approach along with the status of the pedal arch 87 
are still debated (9–12). This issue was investigated in this study using a competing risk 88 
approach.  89 
 90 
Materials and methods 91 
Our vascular surgical centre provides the diagnosis and treatment of CLTI for a population of 1.3 92 
million inhabitants. About 1000 procedures are performed annually for CLTI.  Our threshold for 93 
CLTI is a toe pressure ≤30 mmHg in patients without diabetes and ≤50 mmHg in diabetic 94 
patients, but all cases with an evident arterial stenosis and poorly wound healing, a 95 
revascularization procedure is considered regardless of toe pressure values. The operative 96 
techniques offered have been described in detail in previously published articles (13,14).   97 
Patients included in the present analysis were extracted from our prospectively collected 98 
vascular registry and it was scrutinized retrospectively regarding all variables included to this 99 
study by reviewing patients’ case histories and angiograms. External validation of the vascular 100 
registry had been done and missing cases added annually. In patients who underwent 101 
endovascular treatment, the angiograms before and after the revascularization were reviewed 102 
to define whether the procedure was angiosome-targeted or not. In patients undergoing surgical 103 
bypass, the pre-operative MRI angiograms and all digital subtraction angiograms were reviewed 104 
separately for this analysis. Alltogether 849 patients patients were reviewed, 340 underwent 105 
bypass and 508 patients underwent endovascular revascularization. Of these, there were no 106 
good quality images on pedal arch in 268 patients (167 bypass patients and 101 endovascular 107 
patients). Thus the final number of patients was 580; 173 surgical bypass patients and 407 108 
endovascular patients. 109 
The patency of pedal arch was classified into three categories; complete pedal arch if it was open, 110 
incomplete pedal arch when part of the pedal arch was open but it was partially occluded and 111 
absent pedal arch, when pedal arch was not visible at all and there were only collaterals at the 112 
foot. 113 
The angiosome concept: We defined direct revascularization according to the conventional 114 
method used in our earlier publications as a procedure to the artery supplying the angiosome 115 
affected by tissue loss, with the exception of lesions located in the forefoot or heel (5, 6). For a 116 
tissue defect located in the forefoot, the revascularization of either the anterior tibial/dorsal 117 
pedal artery or the posterior tibial artery/plantar arteries were included in the direct group. If 118 
the patient’s heel was affected, the revascularization of either the posterior tibial or the fibular 119 
artery was classified in the direct group. In cases of a tissue loss spread over several angiosomes 120 
elsewhere besides the forefoot or heel, we adopted the same approach of direct 121 
revascularization as described in the study by Iida et al. – a procedure on the artery supplying 122 
the largest surface of the angiosome involved in the lesion (15). If the patient suffered from 123 
multiple foot ulcers located in separate angiosomes, all affected angiosomes had to be 124 
revascularized in order for the case to be classified into the direct group. 125 
This series includes 580 patients who underwent endovascular and surgical revascularization of 126 
the infrapopliteal arteries for chronic limb threatening ischemia associated with foot ulcer or 127 
gangrene from January 2008 to December 2013.  Only patients with data on the status of the 128 
pedal arch in angiogram were included in the present analysis.  129 
The main outcome endpoint of this series was major lower limb amputation after the index 130 
revascularization procedure. Major amputation was defined as any amputation above the ankle 131 
level. 132 
Statistical analysis 133 
Statistical analysis performed with Stata version 14.0 statistical software (StataCorp LLC, 134 
College Station, TX, USA). Nominal variables were reported as counts and percentages. 135 
Continuous variables were reported as mean with standard deviation. Competing risk method 136 
was employed because death occurring after the index revascularization procedure is a 137 
competing risk, i.e. an adverse event that modifies the chance that major lower limb amputation 138 
is required during follow-up. Univariable and multivariable competing risk analysis was 139 
performed by including variables of relevance with a p<0.2 in the univariable analysis. In any 140 
case, the status of the pedal arch and angiosome-targeted revascularization were included in all 141 
regression models. Risk estimates are reported as subdistribution hazard ratio (SHR) and 95% 142 
confidence interval (CI). A p < 0.05 was considered statistically significant. 143 
 144 
Results 145 
The baseline characteristics and operative data of the included 580 patients, who underwent 146 
either endovascular (n=407) or surgical revascularization (n=173) of the infrapopliteal arteries 147 
for CLTI associated with foot ulcer or gangrene,  are summarized in Table 1. The mean follow-up 148 
of this series was 1.6±1.4 years. At 2 years, survival was 65.1% (no. at risk, 262 patients) and leg 149 
salvage was 76.1% (no. at risk, 212 patients). Wound healing at one year occurred in 67.1% of 150 
patients (no. at risk, 55 patients). 151 
Multivariable competing risk analysis of the overall series showed that C-reactive protein≥ 10 152 
mg/dL, diabetes, rheumatoid arthritis, increased number of affected angiosomes and the 153 
absence of a complete pedal arch were independent predictors of major amputation after 154 
infrapopliteal revascularization. Multivariable analysis showed increasing risk estimates of 155 
major amputation in patients with incomplete (SHR 2.131, 95%CI 1.282-3.543) and no 156 
visualized pedal arch (SHR 3.022, 95%CI 1.553-5.883).  157 
In this series, 324 patients underwent angiosome-targeted revascularization and 100 of them 158 
(17.2% of all patients) had a complete pedal arch whereas 224 patients (38.6% of all patients) 159 
had incomplete pedal arch or no pedal arch at all in the angiogram. Competing risk analysis of 160 
this subset of patients showed that angiosome-directed revascularization in presence of 161 
complete pedal arch had a lower risk of major amputation (SHR 0.463, 95%CI 0.240-0.894) 162 
compared to angiosome-directed revascularization without complete pedal arch when adjusted 163 
for diabetes, C-reactive protein, rheumatoid arthritis and treatment strategy.  164 
A subgroup analysis of patients who underwent bypass surgery and percutaneous transluminal 165 
angioplasty (PTA) was performed and risk estimated of major amputation are summarized in 166 
Table. 2. Diabetes was the only predictor of major amputation in patients who underwent 167 
surgical revascularization (Tab. 2). Among patients who underwent PTA, C-reactive protein>=10 168 
mg/dL, diabetes, rheumatoid arthritis, the number of angiosomes affected, absence of complete 169 
pedal arch and non-angiosome-targeted revascularization were associated with the increased 170 
risk of major amputation. The crude and adjusted amputation rate of the patients who 171 
underwent non-angiosome targeted endovascular revascularization is presented in the Figure 1.  172 
 173 
Discussion 174 
The role of angiosome theory in patients with chronic limb threatening ischemia has been under 175 
debate during the last years. Several retrospective trials showed improved wound healing and 176 
leg salvage in patients undergoing angiosome-targeted revascularization compared to a non-177 
angiosome-targeted one (5,6). Angiosome theory has been criticized as several other factors are 178 
predictors of leg salvage beside the angiosome concept. In the current study we analysed the 179 
factors which are possibly related to the outcome of CLTI including the status of pedal arch. We 180 
found that in addition to increased C-reactive protein, rheumatoid arthritis and numbers of 181 
affected angiosomes, the absence of a complete pedal arch at preoperative angiography was an 182 
independent predictor of poor leg salvage. Among patients who underwent targeted 183 
revascularization, patients with complete pedal arch yielded lower amputation rate compared to 184 
patients without complete pedal arch. Furthermore, angiosome-targeted revascularization was 185 
an independent predictor for leg salvage in patients who underwent endovascular 186 
revascularization.  187 
The role of pedal arch on the outcome after revascularization has been discussed for a long time, 188 
although the quality scientific reports are scarce. Troisi and colleagues (16) studied on the role 189 
of pedal arch in 93 diabetic patients with tissue lesion and ischemia after endovascular 190 
revascularization of the crural arteries. In their analysis, an angiosome-targeted 191 
revascularization did not lead to better wound healing in three months or estimated 1-year 192 
amputation rate, but there was a significant difference in wound healing at three months and 193 
estimated 1-year survival between patients with complete pedal arch (wound healing complete 194 
pedal arch (CPA) vs. incomplete pedal (IPA) arch vs. absent pedal arch (APA) 46% vs. 13% vs. 195 
21%; 1-year leg salvage 100%, 91% and 76% respectively).  However, the number of patients in 196 
different pedal arch groups was rather small as there were only 24-40 patients per groups and 197 
13 patients underwent angiosome-targeted revascularization. Furthermore, analysis was not 198 
adjusted for other comorbidities. Thus, the findings of this study are conclusive.  199 
According to our results, it seems that the presence of a complete pedal arch is beneficial in 200 
terms of outcome of CLTI. These finding couples the results of Higashimori et al. (8), who 201 
observed a significantly higher rate of leg salvage in patients with only one vessel runoff can be 202 
established to the foot, in whom a direct flow into a patent pedal arch was re-established by 203 
endovascular treatment as well as Ricco et al. who found clear association between the existence 204 
of pedal arch and limb salvage (3-yr limb salvage after peroneal bypass 73% in patients with 205 
complete pedal arch vs. 46% in patients with incomplete pedal arch)(10). In our series, 206 
angiosome-targeted revascularization yielded to better leg salvage than non-angiosome-207 
targeted one, and the open pedal arch increased the leg salvage even further among those 208 
patients who received angiosome-targeted procedure. This finding is not surprising as a 209 
complete pedal arch results in to a better outflow and better circulation to the skin and wound 210 
area.  A minority of patients with CLTI have complete pedal arch. In our series, this was the case 211 
in 28% of the patients. In a study with 125 CLTI limbs, a complete pedal arch was observed only 212 
in 18% of cases, However, this study included only patients who had incompressible crural 213 
arteries (ABI>1.4).  It is controversial whether the recanalization of an incomplete or absent 214 
pedal arch leads to better outcome. Several studies reported on endovascular recanalization of a 215 
pedal arch even in cases where it has been totally occluded (14,15). The immediate technical 216 
success has been satisfactory, however no long term patency or outcome data is available.  217 
In our earlier study with 545 patients with diabetes and ischemic tissue lesion, we analysed the 218 
importance of angiosome concept in both surgical and endovascular revascularization. We found 219 
that in patients who underwent surgical bypass, there was no significant difference between 220 
patients who underwent angiosome-targeted bypass versus non-targeted one. However, after 221 
endovascular revascularization, the outcome was clearly better after the targeted PTA compared 222 
to non-targered one. This finding was also noted in our series of 700 patients with CLTI and 223 
tissue lesion with or without diabetes (5). In published meta-analyses on angiosome concept 224 
this difference between surgical and endovascular revascularization has not been verified, 225 
however the number of surgical patients in these has been relatively low and majority of them 226 
do not separate revascularization mode.  In the current study we analysed separately the 227 
predictors for the favourable outcome for surgical and endovascular patients. First of all, there 228 
was no difference between surgical and endovascular revascularization in limb salvage. 229 
Surprisingly, diabetes was the only independent factor associated with the major amputation 230 
after surgical bypass, whereas after endovascular revascularization, there were several 231 
independent risk factors for leg salvage, for example angiosome-targeted revascularization, 232 
complete pedal arch and small number of affected angiosomes. Of course the power of 233 
subanalysis is limited by the small number of patients who underwent bypass surgery. The 234 
reason for significantly lower number of bypass patients was the fact that there was no imaging 235 
of pedal arch in many patients who underwent bypass surgery on the basis of MRI in which the 236 
visualization of pedal arch was compromised. However, our results are in line with the results 237 
from Ricco and colleagues who analysed 120 patients who underwent peroneal bypass due to 238 
CLTI: they did not find association between limb salvage and angiosome targeted bypass after 239 
bypass surgery. In turn, patent pedal arch predicted better leg salvage. (10) 240 
Rheumatoid arthritis had strong independent association with poor leg salvage. There are very 241 
few studies that have examined the clinical outcome of patients with both lower limb arterial 242 
disease and rheumatoid arthritis (16,17). Wound healing studies suggest that the wound healing 243 
is compromised due to altered skin compression and immunosuppressive agents and that 244 
atherosclerosis progression may be accelerated in patients with RA (16). In a very small study 245 
with only 41 RA patients of which one third had claudication and two third had rest pain or 246 
ischemic ulcer, 25 bypass operations were done during 5 year period. Six patients sustained 247 
amputation and the authors concluded that the patients who have RA and LEAD, same 248 
indications should be kept for revascularization than in patients without RA. However, further 249 
studies are needed to better evaluate the prognostic impact of rheumatoid arthritis in patients 250 
with lower limb ischemia. Meanwhile, we recommend to have low threshold for 251 
revascularization pa RA patients with tissue lesion and more close follow-up after 252 
revascularization.  253 
The present results should be viewed in light of some limitations. First, the retrospective nature 254 
of this study might hinder the risk of a bias in the collection of data on the severity of lower limb 255 
ischemia, the degree of infection and the extent of foot lesions. Second, the revascularization 256 
method and the decision on angiosome-targeted strategy were based on the anatomical pattern 257 
and extent of atherosclerosis disease and the feasibility of the revascularization procedure. 258 
Third, angiosome-directed revascularization approach may be less effective in presence of foot 259 
lesions involving multiple angiosomes and render difficult the analysis of these prognostic 260 
factors. Finally, the small size of patients in the surgical revascularization cohort prevented 261 
conclusive results on the determinants of major amputation in this subset of patients. Therefore, 262 
the results of the competing risk analysis in the overall series mostly reflect the results of the 263 
PTA cohort as suggested by similar risk estimates (Tabs. 1-2). Also the lack of WIfI classification 264 
is a limitation as it would give valuable information on the amputation risk. However, we do 265 
have infection and extend of tissue lesion (number of affected angiosomes) on our multivariable 266 
analysis. Only the ABI or toe pressure is missing as the data regarding the hemodynamic values 267 
is incomplete.   268 
 269 
Conclusions 270 
Competing risk analysis confirmed that the extent and severity of infection of the ischemic foot 271 
lesions are independent predictors of major lower limb amputation along with diabetes and 272 
rheumatodid arthritis. Competing risk analysis showed also that a patent pedal arch had 273 
significant impact on leg salvage and that the subset of patients undergoing endovascular 274 
procedure may most benefit of an angiosome-targeted revascularization. 275 
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 343 
  344 
Table 1. Risk estimates of major amputation in competing risk analysis.  345 
  Major amputation 
Baseline covariates 
 
No. (%) / 






Age 74.0 (11.5) 0.369  
Female gender  213 (36.7) 0.791  
C-reactive protein ≥10 mg/dL 363 (62.6) 0.001 2.030, 1.267-3.253 
eGFR (mL/min/1.73 m2) 76.9 (36.9) 0.864  
Dialysis  33 (5.7) 0.647  
Diabetes* 401 (69.1) 0.010 1.984, 1.249-3.153 
Coronary artery disease* 204 (35.2) 0.747  
Heart failure  71 (12.2) 0.848  
Stroke 78 (13.4) 0.986  
Smoker* 83 (14.3) 0.110  
Pulmonary disease* 57 (9.8) 0.096  
Rheumatoid arthritis  37 (6.4) 0.010 2.310, 1.348-3.959 
Gangrene  153 (26.4) 0.604  
No. of angiosomes affected 2.2 (0.9) <0.0001 1.289, 1.069-1.554 
Complete pedal arch  160 (27.6) 0.002 0.447, 0.271-0.738 
PTA vs. bypass surgery 407 (70.2) 0.933  
Angiosome-targeted revascularization 324 (55.9) 0.476  
SHR: subdistribution hazard ratio; CI: confidence interval; PTA: percutaneous transluminal angioplasty; eGFR: 346 
estimated glomerular filtration rate.   (*Diabetes=Diabetes medication or diagnosed diabetes with diet therapy; 347 
Coronary artery disease=CABG, PCI or AMI in history, angina pectoris or ischemia in EKG; Smoker=active smoker or 348 
quitted less than 5 years ago; Pulmonary disease=diagnosed COPD or asthma) 349 
 350 
 351 
  352 
Table 2. Risk estimates of major amputation according to treatment method in competing risk 353 
analysis.   354 
Covariates Multivariate analysis 
SHR, 95%CI 
Bypass surgery  
Diabetes 2.581, 1.030-6.470 
  




Complete pedal arch  0.509, 0.286-0.905 
C-reactive protein ≥10 mg/dl 2.200, 1.106-3.233 
Diabetes 1.891, 1.106-3.233 
Rheumatoid arthritis 2.553, 1.416-4.601 
No. of angiosomes affected 1.366, 1.103-1.691 




Legend of the Figure 1 359 
 360 
Leg survival in patients who underwent non-angiosome targeted endovascular 361 
revascularization (n=192) adjusted with diabetes, number of affected angiosomes, CRP, 362 
rheumatoid arthritis. 363 
 364 
 365 

